Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma

Liao,Juan; Xiao,Jiangwei; Zhou,Yunfeng; Liu,Zilin; Wang,Chunhui

doi:10.3892/mmr.2015.4171

Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma

Authors:
- Juan Liao
- Jiangwei Xiao
- Yunfeng Zhou
- Zilin Liu
- Chunhui Wang
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Gastroenterology, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: August 3, 2015 https://doi.org/10.3892/mmr.2015.4171
Pages: 6065-6071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate changes in cellular immune function and regulatory T cells (Tregs) in patients with hepatocellular carcinoma (HCC) prior to and following transcatheter arterial chemoembolization (TACE) and their clinical significance. The proportion of CD4+ and CD8+ T cells and Tregs in the peripheral blood between healthy volunteers and patients with HCC were detected by flow cytometry prior to (1 day) and one month following TACE. The level of interleukin (IL)‑35 in the peripheral blood was examined by ELISA. In the peripheral blood of patients with HCC, the proportion of CD4+ T cells in the total T lymphocytes was significantly lower compared with that of healthy volunteers (26.71±5.57, vs. 34.74±2.86%; P<0.05) and the ratio of CD4+/CD8+ T lymphocytes in patients with HCC was lower compared with that of healthy adults prior to TACE (1.03±0.14, vs. 1.68±0.16, P<0.05). The ratio markedly increased following TACE treatment (30.52±4.19, vs. 1.29±0.14). The percentage of CD4+CD25+ Treg cells in the total CD4+ T cells isolated from the patients with HCC was markedly higher compared with that of healthy adults prior to TACE (11.12±3.58%, vs. 4.98±1.45%, P<0.05) and it was significantly decreased following TACE (7.58±2.65%; P<0.05). No statistically significant difference in the expression of IL‑35 was detected prior to or following TACE in patients with HCC and healthy adults (369.66±95.53, 352.28±107.50 and 316.24±89.21 pg/ml, respectively). The level of AFP, an oncofetal protein of ~72 kDa, which is produced by normal gastrointestinal cells, yolk sac cells and fetal hepatocytes immediately following birth, was increased in patients with HCC (1674±1649 ng/ml) and was significantly decreased following TACE (827±981 ng/ml). Treg cells changed in positive correlation with the change of AFP, with a correlation coefficient of 0.401. TACE markedly improved the immune function of patients with HCC.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepato cellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	Kew MC: Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma. Pathol Biol (Paris). 58:273–277. 2010. View Article : Google Scholar
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
4	Pedroza-Gonzalez A, Verhoef C, Ijzer mans JN, Peppelenbosch MF, Kwekkeboom J, Verheij J, Janssen HL and Sprengers D: Activated tumor-infiltrating CD4⁺ regulatory T cells restrain antitumor immunityin patients with primary or metastatic liver cancer. Hepatology. 57:183–194. 2013. View Article : Google Scholar
5	Yang ZQ, Yang ZY, Zhang LD, Ping-Bie, Wang SG, Ma KS, Li XW and Dong JH: Increased liver-infiltrating CD8⁺ Foxp3⁺ regulatory T cells are associated with tumor stage in hepato-cellular carcinoma patients. Hum Immunol. 71:1180–1186. 2010. View Article : Google Scholar : PubMed/NCBI
6	Yi Y and He HW: The functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ-and IL-10-dependent manner. J Hepatol. 58:977–983. 2013. View Article : Google Scholar
7	Han KH and Kudo M: Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 81(Suppl 1): 158–164. 2011. View Article : Google Scholar
8	Smith JA, Francis TI, Edington GM and Williams AO: Immunofluorescent localisation of human alpha feto-protein in fetal and neonatal livers and cultured cells from hepatocellular carcinoma. Br J Cancer. 25:343–349. 1971. View Article : Google Scholar : PubMed/NCBI
9	Heger N, Bayindir S, Steckenmesser R and Schirmer H: Percutaneous catheter-arteriographies: Seldinger technique. Minn Med. 53:1093–1097. 1970.PubMed/NCBI
10	Motola-Kuba D, Zamora-Valdés D, Uribe M and Méndez-Sánchez N: Hepatocellular carcinoma. An overview. Ann Hepatol. 5:16–24. 2006.PubMed/NCBI
11	Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC and Kiessling R: Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res. 59:2950–2956. 1999.PubMed/NCBI
12	Sakaguchi S, Yamaguchi T, Nomura T and Ono M: Regulatory T cells and immune tolerance. Cell. 133:775–787. 2008. View Article : Google Scholar : PubMed/NCBI
13	Ke X, Wang J, Li L, Chen IH, Wang H and Yang XF: Roles of CD4⁺ CD25 (high) FOXP3⁺ Tregs in lymphomas and tumors are complex. Front Biosci. 13:3986–4001. 2008.PubMed/NCBI
14	Wing K and Sakaguchi S: Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 11:7–13. 2010. View Article : Google Scholar
15	Jiang S and Lechler RI: CD4⁺ CD25⁺ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. Inflamm Allergy Drug Targets. 5:239–242. 2006. View Article : Google Scholar : PubMed/NCBI
16	Fu J, Xu D, Liu Z, Shi M, et al: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ghiringhelli F, Ménard C, Terme M, et al: CD4⁺ CD25⁺ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 202:1075–1085. 2005. View Article : Google Scholar : PubMed/NCBI
18	Pandiyan P, Zheng L, Ishihara S, Reed J and Lenardo MJ: CD4⁺ CD25⁺Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells. Nat Immunol. 8:1353–1362. 2007. View Article : Google Scholar : PubMed/NCBI
19	Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65:2457–2464. 2005. View Article : Google Scholar : PubMed/NCBI
20	Yang XH, Yamagiwa S, Ichida T, et al: Increase of CD4⁺ CD25⁺ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol. 45:254–262. 2006. View Article : Google Scholar : PubMed/NCBI
21	Shen X, Li N, Li H, Zhang T, Wang F and Li Q: Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol. 136:1745–1754. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zhou J, Ding T, Pan W, Zhu LY, Li L and Zheng L: Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 125:1640–1648. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hoechst B, Ormandy LA, Ballmaier M, et al: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+) CD25(+) Foxp3(+) T cells. Gastroenterology. 135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
24	Yoshizawa K, Abe H, Kubo Y, et al: Expansion of CD4(+)CD25(+) FoxP3(+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma. Hepatol Res. 40:179–187. 2010. View Article : Google Scholar : PubMed/NCBI
25	Cai L, Zhang Z, Zhou L, et al: Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 129:428–437. 2008. View Article : Google Scholar : PubMed/NCBI
26	Unitt E, Rushbrook SM, Marshall A, et al: Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 41:722–730. 2005. View Article : Google Scholar : PubMed/NCBI
27	Zhang HH, Mei MH, Fei R, et al: The frequency, phenotypes and functions of CD4⁺ CD25⁺ regulatory T cells in hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi. 15:266–272. 2007.In Chinese. PubMed/NCBI
28	Collison LW, Workman CJ, Kuo TT, Boyd K, et al: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 450:566–569. 2007. View Article : Google Scholar : PubMed/NCBI